Abstract
Neuroacanthocytosis (NA) syndromes are genetically defined neurodegenerative disorders characterized by the association of red blood cell acanthocytosis and progressive striatal neurodegeneration. The so-called core NA syndromes include autosomal recessive chorea-acanthocytosis and X-linked McLeod syndrome. These two disorders have a Huntington disease-like phenotype consisting of a hyperkinetic, mostly choreatic, movement disorders, psychiatric manifestations, and cognitive decline with a relentlessly progressive course over several decades. In addition, they may have multisystem involvement including motor-dominant axonal neuropathy, myopathy, and cardiomyopathy. McLeod syndrome (MLS) is exceptionally rare with an estimated prevalence of less than 1–5 per 1,000,000 inhabitants. It is caused by mutations in the XK gene. Although the mechanism by which these mutations cause striatal neurodegeneration is not known, the association of the acanthocytic membrane abnormality with selective striatal degeneration suggests a common pathogenetic pathway. Useful diagnostic laboratory tests, besides blood smears to detect acanthocytosis, encompass determination of serum creatine kinase, since virtually all patients with McLeod syndrome reported to date have elevated levels. Cerebral magnetic resonance imaging may demonstrate striatal atrophy. Kell and Kx blood group antigens are reduced or absent, thus delivering an accurate diagnosis of McLeod syndrome, and identification of a distinct mutation in the XK gene is confirmatory. The course of McLeod syndrome is relentlessly progressive, and there is no curative therapy known yet. However, regular cardiologic studies and avoidance of transfusion complications are mandatory. The hyperkinetic movement disorder may be treated as in Huntington disease. Other symptoms including psychiatric manifestations should be managed in a symptom-oriented manner.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allen FH, Krabbe SMR, Corcoran PA. A new phenotype (McLeod) in the Kell blood-group system. Vox Sang. 1961;6:555–60.
Marsh WL, Marsh NJ, Moore A, Symmans WA, Johnson CL, Redman CM. Elevated serum creatine phosphokinase in subjects with McLeod syndrome. Vox Sang. 1981;40(6):403–11.
Walker RH, Jung HH, Dobson-Stone C, Rampoldi L, Sano A, Tison F, Danek A. Neurologic phenotypes associated with acanthocytosis. Neurology. 2007;68(2):92–8.
Jung HH, Danek A, Walker RH. Neuroacanthocytosis syndromes. Orphanet J Rare Dis. 2011;6:68.
Jung HH, Danek A, Frey BM. McLeod syndrome: a neurohaematological disorder. Vox Sang. 2007;93(2):112–21.
Danek A, Rubio JP, Rampoldi L, Ho M, Dobson-Stone C, Tison F, Symmans WA, Oechsner M, Kalckreuth W, Watt JM, et al. McLeod neuroacanthocytosis: genotype and phenotype. Ann Neurol. 2001;50:755–64.
Jung HH, Hergersberg M, Kneifel S, Alkadhi H, Schiess R, Weigell-Weber M, Daniels G, Kollias S, Hess K. McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings. Ann Neurol. 2001;49(3):384–92.
Hewer E, Danek A, Schoser BG, Miranda M, Reichard R, Castiglioni C, Oechsner M, Goebel HH, Heppner FL, Jung HH. McLeod myopathy revisited: more neurogenic and less benign. Brain. 2007;130(Pt 12):3285–96.
Ho M, Chelly J, Carter N, Danek A, Crocker P, Monaco AP. Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell. 1994;77(6):869–80.
Stanfield GM, Horvitz HR. The ced-8 gene controls the timing of programmed cell deaths in C. elegans. Mol Cell. 2000;5(3):423–33.
Rampoldi L, Dobson-Stone C, Rubio JP, Danek A, Chalmers RM, Wood NW, Verellen C, Ferrer X, Malandrini A, Fabrizi GM, et al. A conserved sorting-associated protein is mutant in chorea- acanthocytosis. Nat Genet. 2001;28(2):119–20.
Hayflick SJ, Westaway SK, Levinson B, Zhou B, Johnson MA, Ching KH, Gitschier J. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med. 2003;348(1):33–40.
Walker RH, Rasmussen A, Rudnicki D, Holmes SE, Alonso E, Matsuura T, Ashizawa T, Davidoff-Feldman B, Margolis RL. Huntington’s disease-like 2 can present as chorea-acanthocytosis. Neurology. 2003;61(7):1002–4.
Tschopp L, Raina G, Salazar Z, Micheli F. Neuroacanthocytosis and carbamazepine responsive paroxysmal dyskinesias. Parkinsonism Relat Disord. 2008;14(5):440–2.
Mukoyama M, Kazui H, Sunohara N, Yoshida M, Nonaka I, Satoyoshi E. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes with acanthocytosis: a clinicopathological study of a unique case. J Neurol. 1986;233(4):228–32.
Chauveau M, Damon-Perriere N, Jung H, Latxague C, Spampinato U, Burbaud P, Tison F. Head drops are also observed in the McLeod syndrome. Mov Disord. 2011;26:1562–3.
Gantenbein A, Damon-Perrière N, Bohlender JE, Chauveau M, Latxague C, Miranda M, Jung HH, Tison F. Feeding dystonia in McLeod syndrome. Mov Disord. 2011;26:2123–6.
Miranda M, Jung HH, Danek A, Walker RH. The chorea of McLeod syndrome: progression to hypokinesia. Mov Disord. 2012;27:1701–2.
Jung HH, Brandner S. Malignant McLeod myopathy. Muscle Nerve. 2002;26:424–7.
Oechslin E, Kaup D, Jenni R, Jung HH. Cardiac abnormalities in McLeod syndrome. Int J Cardiol. 2009;132(1):130–2.
Hardie RJ, Pullon HW, Harding AE, Owen JS, Pires M, Daniels GL, Imai Y, Misra VP, King RH, Jacobs JM. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain. 1991;114(Pt 1A):13–49.
Storch A, Kornhass M, Schwarz J. Testing for acanthocytosis A prospective reader-blinded study in movement disorder patients. J Neurol. 2005;252(1):84–90.
Valko PO, Hänggi J, Meyer M, Jung HH. Evolution of striatal degeneration in McLeod syndrome. Eur J Neurol. 2010;17:612–8 (IF: 3.765).
Brin MF, Hays A, Symmans WA, Marsh WL, Rowland LP. Neuropathology of McLeod phenotype is like choreaacanthocytosis (CA). Can J Neurol Sci. 1993;20(Suppl):S234.
Geser F, Tolnay M, Jung HH, Walker RH, Shinji S, Danek A. The neuropathology of McLeod syndrome in neuroacanthocytosis syndromes II. Berlin/Heidelberg: Springer; 2008. p. 197–203.
Margolis RL, Holmes SE, Rosenblatt A, Gourley L, O‘Hearn E, Ross CA, Seltzer WK, Walker RH, Ashizawa T, Rasmussen A, et al. Huntington’s disease-like 2 (HDL2) in North America and Japan. Ann Neurol. 2004;56(5):670–4.
Wihl G, Volkmann J, Allert N, Lehrke R, Sturm V, Freund HJ. Deep brain stimulation of the internal pallidum did not improve chorea in a patient with neuro-acanthocytosis. Mov Disord. 2001;16(3):572–5.
Burbaud P, Rougier A, Ferrer X, Guehl D, Cuny E, Arne P, Gross C, Bioulac B. Improvement of severe trunk spasms by bilateral high-frequency stimulation of the motor thalamus in a patient with chorea-acanthocytosis. Mov Disord. 2002;17(1):204–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag London
About this chapter
Cite this chapter
Jung, H.H. (2014). McLeod Syndrome. In: Micheli, F., LeWitt, P. (eds) Chorea. Springer, London. https://doi.org/10.1007/978-1-4471-6455-5_8
Download citation
DOI: https://doi.org/10.1007/978-1-4471-6455-5_8
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-6454-8
Online ISBN: 978-1-4471-6455-5
eBook Packages: MedicineMedicine (R0)